Publicaciones en colaboración con investigadores/as de University of Paris-Sorbonne (27)

2020

  1. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

    Nature Communications, Vol. 11, Núm. 1

  2. Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (Nature Communications, (2020), 11, 1, (3819), 10.1038/s41467-020-17644-0)

    Nature Communications

2018

  1. Immune effectors responsible for the elimination of hyperploid cancer cells

    OncoImmunology, Vol. 7, Núm. 8

  2. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

    OncoImmunology, Vol. 7, Núm. 6

2017

  1. Trial watch: Immune checkpoint blockers for cancer therapy

    OncoImmunology, Vol. 6, Núm. 11

2016

  1. Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance

    Cancer Cell, Vol. 30, Núm. 1, pp. 147-160

  2. Trial Watch: Immunotherapy plus radiation therapy for oncological indications

    OncoImmunology, Vol. 5, Núm. 9

  3. Trial Watch—Immunostimulation with cytokines in cancer therapy

    OncoImmunology, Vol. 5, Núm. 2

  4. Trial Watch—Oncolytic viruses and cancer therapy

    OncoImmunology, Vol. 5, Núm. 2

  5. Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

    OncoImmunology, Vol. 5, Núm. 6

2015

  1. Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer

    Oncogene, Vol. 34, Núm. 23, pp. 3053-3062

  2. Trial Watch: Adoptive cell transfer for oncological indications

    OncoImmunology, Vol. 4, Núm. 11

  3. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

    OncoImmunology, Vol. 4, Núm. 4

  4. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

    OncoImmunology, Vol. 4, Núm. 4

  5. Trial watch: Naked and vectored DNA-based anticancer vaccines

    OncoImmunology, Vol. 4, Núm. 5

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

  2. Consensus guidelines for the detection of immunogenic cell death

    OncoImmunology, Vol. 3, Núm. 9

  3. Impact of myeloid cells on the efficacy of anticancer chemotherapy

    Current Opinion in Immunology, Vol. 30, Núm. 1, pp. 24-31

  4. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

    OncoImmunology, Vol. 3, Núm. 2

  5. Trial Watch: Toll-like receptor agonists in oncological indications

    OncoImmunology, Vol. 3, Núm. 7